Core Insights - BioCorRx Inc. is focused on improving wellness for individuals struggling with alcohol, opioid, and other addictive disorders, and will present at the Life Sciences Virtual Investor Forum on December 11, 2025 [1][2][5]. Company Highlights - BioCorRx's pharmaceutical subsidiary acquired LUCEMYRA® (lofexidine), an FDA-approved non-opioid medication for mitigating opioid withdrawal symptoms, enhancing the company's product portfolio [6][9]. - The company reported significant revenue growth, with Q3 2025 revenue reaching $635,224 compared to $0 in Q3 2024, and a reduced net loss of $808,502 compared to $1.5 million in Q3 2024 [9]. - For the first half of 2025, BioCorRx experienced a 3,985% revenue growth to $313,000, and a 4,306% growth to $178,000 in Q2 2025, driven by LUCEMYRA sales [9]. - An updated research note from Diamond Equity Research in November 2025 provided additional visibility on the company's revenue ramp driven by LUCEMYRA [9].